Tech Support


This line is for technical support.
For General Enquiries please click General Contact

On-Demand Webinar

Clinically Relevant Cell-Based Solutions for Target Identification

Presenter: Michelle Mack
Target Identification Webinar

Target identification studies play a critical role in the early stages of cancer drug discovery and development. The objective of these studies is to understand disease mechanisms, so targets for drug intervention can be identified and used to discover lead compounds.

Access to the following cell-based solutions are needed to accelerate contemporary target identification studies:

  • Clinically relevant cell lines that express appropriate disease biology, genetics (e.g. mutations, fusions), biomarkers, or a varying panel of these factors

  • Reliable assays incorporating a variety of analytical techniques to verify that a target is expressed or inhibited

  • In vitro linked models and assays to progress preclinical development via a swift and seamless transition to ex vivo or in vivo studies

Watch this webinar to learn how to:

  • Gain access to one of the largest banks of well-characterized, clinically relevant cell lines

  • Use large-scale cell screening across a variety of cancer types or subtypes to identify targets

  • Apply robust proteomic and genomic assays to evaluate targets and lead compounds

  • Make a seamless transition using matched in vitro and in vivo models to progress to the next stage of development

Watch Now!

About The Presenter: Michelle Mack

Michelle Mack, Crown Bioscience Inc webinarMichelle Mack, Director of Scientific Engagement at Crown Bioscience brings 15 years of previous Oncology R & D experience from Pfizer Inc., where she was a Senior Scientist in the Oncology Research Unit and served as a research project leader on oncology therapeutic programs. At Pfizer, she led cross-functional teams exploring approaches that included: small-molecule inhibitors, antibody drug conjugates and nanoparticle based therapeutics. Michelle’s scientific expertise span’s the preclinical and translational space for multiple solid and hematological tumor indications. Throughout her professional career, Michelle has worked in Oncology, Immunology and Immuno-Oncology therapeutic areas. She has several high-impact peer-reviewed publications and has led discussions at multiple scientific conferences. Michelle obtained her undergraduate degree from Rochester Institute of Technology, Rochester, NY. She then received her M.S. in microbiology and is currently completing her Ph.D. in molecular biology from Seton Hall University.

Watch Now!

Your privacy is important to us.
We'll never share your information.